Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib + platinum doublet chemotherapy + pembrolizumab vs placebo + platinum doublet chemotherapy + pembrolizumab in metastatic non-squamous NSCLC (China cohort of MK-7902-007/KEYNOTE-XYZ)
CTR20191820Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of lenvatinib, pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by Merck & Co.. Started Sep 2019; status: completed.
02
Drugs
lenvatinibpembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20191820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191820.